View all veterinary jobs
The maker, MSD Animal Health, says Numelvi is "the first and only “second-generation” Janus kinase (JAK) inhibitor indicated from six months of age (and 3kg) for the treatment of pruritus associated with allergic dermatitis, including atopic dermatitis, as well as the clinical manifestations of atopic dermatitis in dogs. .
It is given once daily and MSD says it is clinically effective after the first dose.
The company says itch relief begins within 2–4 hours and dosing is one tablet a day from day one.
MSD claims Numelvi is at least 10 times more selective for JAK1 compared with other JAK family members (JAK2, JAK3 and TYK2).
Numelvi can be used concurrently with vaccines (including rabies) and other common treatments such as ectoparasiticides, with no requirement for routine blood and urine monitoring.
Dermatology specialist Dr Debbie Gow said: “Second-generation JAK inhibitors are selective — specifically, in this case, more selective for JAK1 than other JAK enzymes.
“The high selectivity for JAK 1 contributes to the favourable safety profile of Numelvi.”
Dr Sue Paterson MA VetMB DVD DipECVD FRCVS added: “Treating canine allergic dermatitis means offering treatment which relieves itch and inflammation, whilst managing any unwanted side effects.
"We want to inhibit JAK 1 to reduce itch and inflammation, whilst having little to no effect on other JAK family members.”
MSD Animal Health will host a lunch-and-learn digital launch event with The Webinar Vet on Thursday 26 March, aiming to set a Guinness World Record for a veterinary educational launch event.
DuOtic contains terbinafine, an antifungal, and betamethasone acetate, a corticosteroid.
One tube is administered per affected ear, with a second dose given after seven days.
The maximum clinical response may be seen up to 21 days after the second dose
The product was unveiled earlier this year at an event attended by around 80 vets and nurses, where speakers discussed the importance of a holistic approach to otitis externa and the need for judicious antibiotic use.
Speaking at the event, Tim Nuttall said that antibiotic use “has consequences in terms of antimicrobial resistance and should only be used when justified”.
Speakers highlighted that effective management of otitis externa depends on identifying and addressing primary, predisposing, secondary and perpetuating factors, and on implementing a targeted two-phase treatment approach, comprising induction followed by long-term maintenance.
Routine dermatological assessment, including whole-skin examination, otoscopy and cytology, was emphasised as essential to identifying underlying causes and guiding treatment selection.
The role of the wider veterinary team, including trained veterinary nurses, and clear communication with dog owners were also recognised as key to improving outcomes in yeast-only otitis externa.
https://www.dechra.co.uk/products/dog/prescription/duotic
The College says the findings address evidence gaps from previous research and highlight the importance of routine veterinary otoscopic ear checks.
Although previous research has suggested that lop-eared rabbits may be more susceptible, the researchers say it relied on small samples and retrospective clinical records or owner reports.
For this study, RVC Rabbit Welfare Research Assistants, Maria Jackson RVN and Michaela Betts MRCVS, examined 435 pedigree rabbits volunteered by British Rabbit Council (BRC) breeders.
Between October 2023 and February 2024, the team travelled to BRC shows and breeding studs to record each rabbit’s ear type, head shape, estimated adult bodyweight, age and other features before performing a structured otoscopic examination in which the outer ear, the diverticulum and the full length of the external ear canal were checked for signs of inflammation, narrowing, discharge or crusting.
By combining these observations with multivariable statistics, the team was able to compare ear health across 49 breeds and identify which conformations were most strongly associated with specific ear abnormalities.
The results showed that ear shape plays a central role in predisposing rabbits to hidden ear disease.
Lop-eared rabbits were more likely to show 9 of the 11 abnormalities assessed, including ear canal narrowing, abnormal colour, flaky and wet discharge, behavioural reactivity to ear examination, dermatological changes to the pinna and crusts in the diverticulum.
The shape of a rabbit’s head was also associated with the types of ear problems they were likely to develop, but not in a consistent manner.
Brachycephalic rabbits had narrower ear canals, while dolichocephalic rabbits were more likely to have crusts in the diverticulum.
Body size mattered too, with heavier rabbits more likely to show problems such as redness, narrowing, flaky discharge and traumatic pinna changes, as well as stronger behavioural reactions during examination.
Other physical and signalment factors showed mixed results, highlighting the complexity of ear health across breeds.
Maria said: “Our findings have once again shown that rabbits with lop ears are more likely to develop ear problems – specifically, signs of otitis externa – than rabbits with upright ears."
Dr Charlotte Burn, Associate Professor in Animal Welfare and Behaviour Science at the RVC, and senior author on the paper, said: “This is the first study to have directly and systematically examined rabbit ears outside a clinical context, and it confirms that the seemingly endearing shape of lop rabbits’ ears really do risk deeper ear disorders.
"Alongside the physical changes we observed, we documented rabbit behaviour, such as avoidance, shaking their heads and scratching at their ears, and found that the lop-eared rabbits reacted significantly more to having their ears examined than rabbits with ‘up’ ears.
"To me, this indicates that their ears were not only physically affected, but they also hurt more, highlighting the animal welfare burden of this hidden problem.”
References
The company says Nutramed kills over 99.9% of known bacteria and fungal spores whilst being safe and gentle enough for use on sensitive areas such as around the eyes and mouth.
Lianne O’Boyle RVN and Clinical Lead at Nutravet, said: “Veterinary professionals need a reliable, safe and effective solution for minor wound management and first aid.
"Nutramed hypochlorous spray and gel combine powerful antimicrobial performance with a gentle formula, making it a must-have in every practice and pet owner’s first aid kit.
“Designed to support everyday veterinary care, Nutramed provides peace of mind for professionals and pet owners alike by ensuring minor wounds, cuts, and abrasions are treated quickly and effectively.”
www.nutravet.com.
Designed to help veterinary teams make clearer, more confident clinical decisions, the flowchart provides a step-by-step approach to diagnosing and managing ear disease in dogs and cats.
Renzo Di Florio, Technical Veterinary Adviser at Krka UK, said: “It takes you through each step, from diagnosis to treatment and long-term management, including identifying cases that might benefit from referral.
"It can also help practices to develop an otitis externa management plan protocol that’s useful for the whole team, and that’s practical and easy to integrate into existing workflows.”
One of the main messages in the flowchart is the central role of cytology in otitis management.
Tim said: “Cytology is essential to assess the level of inflammation and detect the presence of bacteria or Malassezia.
"This helps clinicians make informed decisions about whether antibiotics are truly needed.
"In contrast, culture and sensitivity testing can be misleading when used to guide topical therapy.”
https://www.krka.co.uk/veterinary-knowledge-hub
The guidelines, which are the result of a collaboration between veterinary dermatologists, clinical microbiologists and other specialists, are designed to reduce inappropriate antimicrobial use and help canine welfare.
The team conducted an evidence review and built a consensus of recommendations, combining scientific evidence with real-world insights.
The new guidelines are supported by the ISCAID (International Society for Companion Animal Infections) and provide veterinary practitioners with guidance on the diagnosis and investigation of canine bacterial skin infections.
The guidelines offer recommendations for when antimicrobials should be considered, and which classes of antimicrobials are most appropriate to choose from.
As part of this guidance, recommended drug dosages have also been updated based on newly available information.
The RVC says this will ensure that available antimicrobial drugs can be used as responsibly as possible and remain effective for a long as possible.
RVC has also produced a short synopsis of the main consensus statements and a ‘Seven Moments of Responsible Canine Pyoderma Treatment’ infographic.
Anette Loeffler, Professor in Veterinary Dermatology and Cutaneous Bacteriology at the RVC and chair of the ISCAID author group, said: “After several years of analysing evidence, updating information and evaluating experience, we are excited and relieved to finally see the guideline documents published and free to use around the world.”
https://pubmed.ncbi.nlm.nih.gov/40338805
Zenrelia is a new JAK inhibitor which Elanco says provides visible itch relief which lasts 24 hours, from the first dose.1
The company points to a head-to-head study with over 330 dogs across 25 vet clinics, in which Zenrelia was shown to get 45% more itchy dogs back to normal than Apoquel (oclacitinib).1
Elanco says its once-daily dosing may also improve treatment compliance over twice-daily alternatives.
The company also says that Zenrelia has a cost benefit too, presumably meaning it's cheaper than alternatives.
Zenrelia can be given long term with commonly used medications, including vaccines, antibiotics, parasiticides and NSAIDs.
Elanco UK & Ireland General Manager Matthew Frost said: “With this treatment, we’re looking at happier dogs and their owners, and a more rewarding experience for vets.”
www.zenrelia.co.uk
Reference
The research was carried out by scientists from Wisdom Panel, a pet DNA testing company that is part of Mars Petcare’s Science & Diagnostics division.
The discovery was made by analysing clinical data from Banfield Pet Hospital paired with DNA data from Wisdom Panel.
The researcher say estimates suggest canine atopic dermatitis affects up to 10-30% of dogs, and that these findings could lead to more targeted solutions in the future.
In addition, identification of the SLAMF1 variant presents the opportunity for breeders to breed toward dogs with a lower risk of atopic dermatitis.
Jimmy Barr, DVM, DACVECC, Chief Medical Officer for Mars Petcare’s Science & Diagnostics division said: “This finding could have a real impact on dog health
"While atopy has long been suspected to have a genetic component, this is the first time the SLAMF1 gene has been convincingly linked to this debilitating skin condition.
"This knowledge will help identify dogs at risk and could lead to new therapies and more informed dog breeding practices.”
Wisdom Panel has developed a DNA test that will be offered in partnership with Canine Genetic Testing at the Department of Veterinary Medicine, University of Cambridge so breeders can make informed decisions to reduce the frequency of atopic dermatitis while maintaining genetic diversity.
https://www.cagt.co.uk/
Photo: https://depositphotos.com
Conducted as a multicentric international study involving board-certified veterinary dermatologists, the trial included 35 dogs with CIF in at least two paws.
Each dog acted as its own control, and was treated with systemic antibiotics, with one paw being treated with FLE and the other paw without.
Paws were allocated based on a coin toss, and the study was single blinded: the principal investigator was responsible for the assessment of lesions, and the co-investigator was responsible for administration of FLE treatment.
The dogs were assessed over an 8-week period with check-ups every 14 days.
At every check-up the paws treated with FLE showed a greater improvement than paws without FLE treatment.
The lesions were assessed and scored with the global lesion score, the pruritic visual analogue scale, a cytological scoring, and photographic documentation.
The results of the study demonstrated that FLE combined with systemic antibiotics significantly reduced the time to clinical resolution compared to antibiotics alone.
By week four, 50% of paws in the FLE group had reached clinical resolution compared to 17% in the control group.
By week eight, 88% of paws in the FLE group had healed compared to 54% in the control group.
Dr Anja Lange, DVM, Department of Dermatology, AniCura Kleintierspezialisten Augsburg GmbH, Augsburg, Germany, said: “Canine interdigital furunculosis is a challenging condition to treat that can be prolonged and frustrating.
"Having FLE as an additional management tool is very exciting, not least because it speeds up time to healing, but it also requires us to use less antibiotics.
"The use of FLE was well accepted by all of the dog owners from the study and the dogs themselves tolerated it well, showing it can be a very useful adjunct to cases in clinical practice.”
The five-minute survey includes questions on the number of otitis externa cases seen in practice, consultation times, common compliance issues, cytology uptake and client behaviour change frameworks.
Completed entries will be entered into a draw for a Fortnum & Mason hamper worth £100.
Charlotte Hill, brand manager at Dechra said: “The otitis externa in dogs survey will provide us with valuable insight into vets’ experiences of the condition.
"It will also allow us to identify any trends that may exist to help us improve how we as a profession approach otitis externa, while supporting owners when treating the condition which can be frustrating to manage.
https://forms.office.com/e/J7frrbL56A
The new platform offers video tutorials, podcasts, webinars, scientific studies, blogs and downloadable resources, all designed to ensure users understand how the HT Vista screening device can support their day-to-day work.
Users can also ask for a free one-on-one training call with HT Vista for personalised guidance.
HT Vista’s Managing Director, Liron Levy-Hirsch said: “We’re excited to introduce this new platform for veterinary professionals alongside our latest diagnostic update to the device.
"Our goal with HT Vista Academy is to support users in expanding their expertise, not just in operating the device but also in understanding the technology behind it and learning the best practice of dermal and subcutaneous mass management.
"By offering valuable educational resources and hands-on support, we hope to enhance the overall experience for veterinary teams and, ultimately, the care they provide to their patients.”
The company says the screening device is being widely used in nurse clinics around the world and its academy is suitable for both vets and veterinary nurses.
www.ht-vet.com/academy
The guidance was written by Hany Elsheikha, Head of the European Scientific Counsel for Companion Animal Parasites (ESCCAP).
For a copy of the bulletin, contact your Zoetis Account Manager or call Customer Support on 0345 300 8034.
Otomicol contains miconazole nitrate, prednisolone acetate and polymyxin B.
The product targets a range of pathogens including miconazole and polymyxin B-sensitive, Malassezia and Pseudomonas spp.
Renzo Di Florio, technical vet at Krka UK, said: “With its multifactorial aetiology, ear disease is often challenging to manage, causing frustration for owners and significant discomfort for pets.
"Otomicol is a cost-effective solution that veterinary surgeons can add to their treatment toolbox for cases where bacterial and fungal infection are important factors.”
Otomicol ear drops and cutaneous suspension are available in a 15ml bottle with an extended shelf life of six months after opening.
Otomicol is available from veterinary wholesalers.
https://www.krka.co.uk
Nutraotic contains grapeseed oil, cinnamon, oregano, clove and lemongrass, a formulation which Nutravet says is designed to provide anti-bacterial, anti-fungal and anti-inflammatory support.
The company claims it helps cleanse and moisturise the ear canal, reduce ear odours and break down earwax, while maintaining a balanced ear flora to help prevent infections.
Chris Jones, Managing Director of Nutravet said: “Our goal with the Nutraotic range is to provide pet owners and veterinary professionals with products that offer safe, natural solutions to common pet ear issues.
“We recognise that ear health in dogs and cats is a frequent concern, and with the launch of the Nutraotic Ear Essential Oil, we’re expanding our ability to support pets in a way that’s effective and gentle.
"This product has been developed to make ear care simple and stress-free while using only the highest quality ingredients.”
www.nutravet.com
The Nutraotic range includes ear wipes and an ear cleaner, both formulated to provide anti-fungal and anti-bacterial support while moisturising, soothing, and hydrating the skin.
The products are scented with fresh cucumber and melon.
Chris Jones, Managing Director of Nutravet, said: "Our goal at Nutravet has always been to develop the best veterinary strength, healthcare products to aid and support a pet's wellbeing.
"Ear health in dogs and cats is a common concern for many pet owners, and these products give practices high-strength solutions to offer their clients."
'Otitis Externa: Understanding Ear Disease’ will be presented by RCVS Recognised Specialist in Veterinary Dermatology, Former Member BVetMed CertSAD DVD PhD PgCAP FHEA MRCVS (pictured).
Virbac says the webinar will explain how Cortotic can help practices reduce antimicrobial use when treating otitis externa in dogs, whilst offering the same efficacy as a fixed-combination product.
https://bit.ly/CortoticWebinar
Cortotic contains hydrocortisone aceponate (HCA), a diester glucocorticosteroid to reduce inflammation.
In a clinical field study, published in Veterinary Dermatology, Cortotic was shown to be as effective in treating acute otitis as a fixed-combination product containing a corticosteroid, an antibiotic and an antifungal, with an equivalent improvement of clinical and cytological scores1.
A secondary reduction of bacterial and yeast overgrowth was demonstrated and a concomitant treatment with an antimicrobial was unnecessary.
The product was shown to provide rapid relief from clinical signs, pruritus and pain1.
Virbac says the lipophilic nature of the HCA diester provides enhanced penetration into the skin, a reservoir effect and low plasma availability for high local activity with reduced systemic secondary effects2.
Chris Newark, Product Manager at Virbac said: "With Cortotic we’re excited to offer clinicians the ability to reduce antimicrobial usage when treating otitis externa in dogs, whilst offering the same efficacy as a fixed-combination product.
"The product’s easy administration also makes it an attractive choice for pet owners with 94% of owners stating that they would choose to use Cortotic again3".
Cortotic is presented in an ear spray device with atraumatic cannula, which delivers a fine mist spray for even application.
Dosing is 2 pumps per application, whatever the dog’s size, once a day for 7-14 days.
The ‘Ear essentials – a holistic approach to the treatment of canine otitis externa’ webinar will include a presentation by Jonathon Elgie, veterinary technical advisor at Dechra UK and Ireland.
Jonathon will talk delegates through case examples to help them make decisions that can be used in practice and take a clear, practical and holistic approach to treatment.
He will also update vet professionals on Dechra support including the Lifelong Ear Partnership which provides education, tips and assistance to achieve better clinical outcomes and owner satisfaction.
Containing 3% m/v Chlorhexidine, Pyoderm is designed to support the natural microbial balance of the skin whilst delivering gentle yet effective cleansing.
Along with the rest of Virbac's range of dermatological and everyday care shampoos, Pyoderm is presented in 250ml eco-friendly bottles which are made from 100% recycled plastic and recyclable packaging.
The shampoos themselves are also biodegradable.
https://uk.virbac.com/
Despite being a common disease, CVS says very little research has been undertaken into EPD in the UK.
In addition, numerous different treatments are currently used for EPD, for which there is not always robust scientific evidence.
The CVS study, which started in 2022 and will continue till early 2024, involves 20 practices.
Samples have been collected from over 70 cases from horses that have been diagnosed by EPD throughout the UK.
Full blood profiles have been assessed, in addition to bacterial culture analysis of the lesions, PCR analysis for dermatophytes (ringworm fungi), microscopy for ectoparasites (mites) and skin cytology.
An owner questionnaire has also been completed to gather information on EDP management.
Each horse’s lesions have been graded and descriptive data relating to the lesions were recorded.
Data collection is now complete and a team of researchers, led by vet Manuela Diaz Ramos, has started analysing the data.
A full report on the findings, along with treatment and management recommendations, is expected to be presented at a scientific conference later this year.
The CVS practice aimed to change its prescribing culture by adopting an evidence-based, case-by-case approach and supporting its vets in only using antibiotics where absolutely necessary.
The practice identified the use of antibiotics in the treatment of cat bite abscesses (CBAs) as worthy of investigation.
Cefovecin, a third-generation cephalosporin and critically important antibiotic, is often used in the treatment of CBAs.
The practice first sought guidance from a dermatology specialist with an active research programme involving the study of antimicrobial resistance (AMR).
It then developed a clinical guideline advising that if a cat has a discrete abscess, with no pyrexia (raised temperature) and no cellulitis, antibiotics are not required.
White Lodge then conducted an eight-month clinical audit across its Exmouth Hub, with the aim of measuring the effect of the new guideline.
The practice treated patients with CBA’s with NSAIDS, lancing and flushing (if necessary), and cleaning of the abscess.
Owners were advised to flush the affected area at home once daily.
An antibiotic awareness leaflet was given to clients with an explanation of the reasoning behind not prescribing antibiotics.
Cats presented 5-7 days after treatment for a nurse re-examination.
A consultation template was created for both the vet at initial presentation and another for the nurse’s post treatment check, to gather standardised information.
The measure of successful treatment was whether, on re-examination, the CBA site appeared free from infection and wound healing was evident.
If the wound had not started to heal or if there was infection or pyrexia, the treatment was deemed to have failed and further treatment was provided.
Analysis of the results showed that of the 22 cats included in the audit, 19 (86%) did not need antibiotics to successfully treat the abscess.
There was also a 32.6% reduction in the number of times cefovecin was dispensed in the eight-month period after the audit started, compared with the previous eight months.
Emily Parr, Head Veterinary Surgeon at White Lodge, said: “We think, due to lack of confidence in treatment without antibiotics as well as client pressure or expectation, the profession tends to default to the prescribing of antibiotics.
“However, this clinical audit has given our veterinary colleagues increased confidence in treating CBA’s without antibiotics.
"There has also been an improved client understanding in accepting treatment without antibiotics.
"Clients have also been positive when minimal intervention has been required, particularly as it eliminates the cost of antibiotics.
"This has had a positive impact on the vet-client relationship and trust in our practice.
“Antimicrobial resistance is continuing to threaten the efficacy and treatment of an ever-increasing range of infections.
"So we hope that our CBA clinical audit outcome results will help to set a benchmark and shape clinical guidelines for the wider veterinary profession in this area.”
The 'Lifelong Ear Partnership' resources, which were developed in conjunction with a panel of vets, are designed to help practice teams improve their owner communication and achieve owner buy-in about otitis.
To that end, Dechra has developed various owner communication tools for use in practice or to refer owners to after the consultation.
They include an owner website: www.ear-inflammation.co.uk and a postcard with QR code links to educational videos which cover clinical recommendations, treatment options and the importance of revisits.
There is also a brochure for owners and an online 4D ear model: www.4d-earmodel.com, which demonstrates a healthy ear and an ear with mild, moderate or severe otitis.
Finally, Dechra has also launched an ear cytology webinar series on Dechra Academy: www.dechra.co.uk/academy.
The course consists of tips for everything from greeting the patient to performing and interpreting cytology slides.
www.dechra.co.uk/otitis-externa.
Phovia, which was launched in the UK last year, is a two-part FLE system consisting of a chromophore gel that is applied to the affected skin and a blue light LED lamp.
Vetoquinol says that when used together they produce light of varying wavelengths that penetrates the skin to different depths, helping to control bacteria and reduce inflammation on the surface of the skin and stimulating regeneration in the epidermal and dermal layers.
The unit is portable, and applications take four minutes once a week.
The authors of the Vetoquinol-funded study say that FLE has already been shown to support and accelerate natural skin healing, but this latest research shows that the benefits go beyond improvement in clinical signs.
The study looked at 35 dogs with a diverse range of skin conditions: 13 had interdigital furunculosis, 10 had deep pyoderma, 6 had wounds, 4 had pyotraumatic dermatitis, and 2 had perianal fistula on presentation.
Eight of 35 dogs were new cases, whereas the remaining 27 were undergoing recrudescence of a prior episode, including pyotraumatic dermatitis, wounds, deep pyoderma, interdigital furunculosis and perianal fistulae.
Thirty dogs (86%) achieved a clinical resolution: 18 with the Fluorescent Light Energy alone and 12 with the concomitant use of FLE and topical antiseptic shampoo.
Five dogs (14%) had a partial response and needed other therapies.
92% percent of owners attested to their pet’s enhanced quality of life, with 74% of dogs displaying at least a 50% improvement in owner-reported behaviour, mood, sleep and playing activities.
The study also reported a 46% reduction in caregiver burden.
Felicity Caddick, Technical Services Manager at Vetoquinol said: “Managing skin conditions often requires the long-term use of shampoos or topical therapies.
"Many owners find this aspect of pet ownership challenging, especially with larger dogs, or less cooperative animals.
"FLE can reduce or in some cases eliminate the need for topical therapies at home, not only simplifying the treatment process but also enhancing convenience and compliance.
"Sharing responsibility for administering ongoing treatment with their vet practice also removes some of the worry associated with their pet’s health.”
Vetoquinol also highlights that Phovia can offer vets a drug-free management option for skin disorders that aligns with the principles of antibiotic stewardship.
Zoetis has added a dermatology application to its Vetscan Imagyst, which promises to reduce the time it takes GP veterinary surgeons to analyse skin samples by as much as half.The new Vetscan Imagyst AI dermatology application analyses impression smears and ear and skin swabs to identify yeast, inflammatory cells and bacteria.
It provides results in about ten minutes, depending on your upload speeds, which VetSurgeon understands is probably how long a dermatologist would take to perform the task (compared to a GP, who might take twice as long, depending on skills, available equipment, volume of tests, etc).
In terms of accuracy, Zoetis says the application is comparable to that of a clinical pathology expert.
In addition, it fires out a report, including images, which can be shared with the client, adding more value to the consultation.
According to a 2006 study, something like 72% of vets' derm diagnosis and treatment recommendations are based on presenting clinical signs and physical examination alone1.
Vetscan Imagyst list price is just shy of £18,000, but there are a variety of commercial deals that can be discussed with your Zoetis Account Manager. Each AI analysis costs in the order of a tenner.
So the question is whether the new system is worth the investment - for the 72% in terms of a more accurate diagnosis over an educated guess, and for the 28% in terms of the time-savings over a manual analysis.
Sophie Duguid, Diagnostics National Veterinary Manager at Zoetis UK said: “The ability to accurately and reliably identify inflammatory cells, bacteria and yeast, at the time of visit can make a huge difference for busy clinics, ensuring better outcomes and happier patients and owners.
"Performing cytology is a critical component of the dermatology work-up, however this can often be challenging for veterinary healthcare teams to deliver given the considerable time pressures in clinical practice.
"Vetscan Imagyst AI dermatology allows clinicians to rapidly detect the presence or absence of skin infection in canine and feline dermatology cases which allows for clinically informed decision making."
Hill PB et al; Survey of the prevalence, diagnosis and treatment of dermatological conditions in small animals in general practice. Veterinary Record (2006) 158, 533-539
Worth two hours of free CPD, the course has eight bitesize modules of between five and 15 minutes.
Each session is designed to improve confidence in cytology, in particular knowing when it is needed and how to take and interpret skin and ear cytology samples.
The course also includes advice on the use of dermatopicals and how to choose between Douxo S3 Pyo and Douxo S3 Calm.
The modules are presented by Natalie Barnard BVetMed, a European Veterinary Specialist in Dermatology, Amy Elvidge, an RCVS Recognised Specialist in Veterinary Dermatology, and Daniel White, a Dermatology Veterinary Nurse.
Emelie Fogelberg BSc DVM MRCVS, veterinary advisor at Ceva Animal Health said: “Skin problems can be challenging, and recurrent skin irritations are particularly frustrating.
"Cytology is essential in the work up of these cases but is often overlooked.
“Our new skin and ear cytology online course will help both vets and nurses become more confident in sample taking and interpretation to support a diagnosis and management plan from the first consultation.”
To register, visit https://veterinarywebinars.com/community/ceva/.
www.douxo.com